

# A Systematic Review and Meta-Analysis on the Effects of Exercise on the Endocannabinoid System

Shreya Desai,<sup>1</sup> Breanna Borg,<sup>1</sup> Carrie Cuttler,<sup>2</sup> Kevin M. Crombie,<sup>3</sup> Christine A. Rabinak,<sup>1,4-6</sup> Matthew N. Hill,<sup>7</sup> and Hilary A. Marusak<sup>1,6,\*</sup>

## Abstract

**Introduction:** The endocannabinoid (eCB) system plays a key role in maintaining homeostasis, including the regulation of metabolism and stress responses. Chronic stress may blunt eCB signaling, and disruptions in eCB signaling have been linked to stress-related psychiatric disorders and physical health conditions, including anxiety, depression, post-traumatic stress disorder (PTSD), diabetes, and obesity. Pharmacological and nonpharmacological behavioral interventions (e.g., exercise) that target the eCB system may be promising therapeutic approaches for the prevention and treatment of stress-related diseases. In this study, we perform a systematic review and the first meta-analysis to examine the impact of exercise on circulating eCB concentrations.

**Materials and Methods:** We performed a review of the MEDLINE (PubMed) database for original articles examining the impact of exercise on eCBs in humans and animal models. A total of 262 articles were screened for initial inclusion.

**Results:** Thirty-three articles (reporting on 57 samples) were included in the systematic review and 10 were included in the meta-analysis. The majority of samples that measured anandamide (AEA) showed a significant increase in AEA concentrations following acute exercise (74.4%), whereas effects on 2-arachidonoylglycerol (2-AG) were inconsistent. The meta-analysis, however, revealed a consistent increase in both AEA and 2-AG following acute exercise across modalities (e.g., running, cycling), species (e.g., humans, mice), and in those with and without pre-existing health conditions (e.g., PTSD, depression). There was substantial heterogeneity in the magnitude of the effect across studies, which may relate to exercise intensity, physical fitness, timing of measurement, and/or fasted state. Effects of chronic exercise were inconsistent.

**Conclusions:** Potential interpretations and implications of exercise-induced mobilization of eCBs are discussed, including refilling of energy stores and mediating analgesic and mood elevating effects of exercise. We also offer recommendations for future work and discuss therapeutic implications for exercise in the prevention and treatment of stress-related psychopathology.

**Keywords:** anandamide; mental health; endocannabinoids; physical activity; running

## Introduction

The endocannabinoid (eCB) system plays a key role in maintaining homeostasis throughout the brain and body, including regulating energy metabolism, cognition, sleep, inflammation, and stress responses.<sup>1-3</sup> eCB

receptors, including cannabinoid type-1 (CB1Rs) are located throughout the brain and play a neuromodulatory role in various neurotransmitter systems.<sup>4,5</sup> Although they are widespread, CB1Rs are most densely located in limbic brain regions (e.g., including the prefrontal

<sup>1</sup>Department of Psychiatry and Behavioral Neurosciences, School of Medicine, Wayne State University, Detroit, Michigan, USA.

<sup>2</sup>Department of Psychology, Washington State University, Pullman, Washington, USA.

<sup>3</sup>Department of Psychiatry and Behavioral Sciences, University of Texas at Austin, Austin, Texas, USA.

Departments of <sup>4</sup>Pharmacy Practice and <sup>5</sup>Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.

<sup>6</sup>Merrill Palmer Skillman Institute for Child and Family Development, Wayne State University, Detroit, Michigan, USA.

<sup>7</sup>Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

\*Address correspondence to: Hilary A. Marusak, PhD, Department of Psychiatry and Behavioral Neurosciences, School of Medicine, Wayne State University, 3901 Chrysler Service Drive., Suite 2B, Detroit, MI 48202, USA, E-mail: hmarusak@med.wayne.edu


cortex, amygdala, and hippocampus)<sup>6</sup> implicated in stress and emotion regulation, reward processes, fear learning, and extinction. Cannabinoid type-2 receptors (CB2Rs) are found on immune tissues and play an immunomodulatory role in cytokine release.<sup>7</sup>

The two most well-studied eCBs (i.e., endogenous ligands for cannabinoid receptors) are anandamide (AEA) and 2-arachidonoylglycerol (2-AG). These eCBs are synthesized “on demand” and released into the synapse from the post-synaptic neuron to inhibit pre-synaptic activity in a retrograde manner.<sup>8–10</sup> Activity of AEA and 2-AG is primarily modulated by enzymes that synthesize (i.e., N-acylphosphatidylethanolamine phospholipase D [NAPE], diacylglycerol lipase [DAGL], respectively) or catabolize (i.e., fatty acid amide hy-

drolase [FAAH], monoacylglycerol lipase, respectively) eCBs.

In addition to regulating synaptic activity, eCBs can inhibit activity of the hypothalamo–pituitary–adrenocortical axis and the sympathetic nervous system.<sup>11,12</sup> eCB concentrations are modulated in response to both acute and chronic stress exposure,<sup>13</sup> and disruptions in eCB signaling are linked to several stress-related diseases, including anxiety, depression, post-traumatic stress disorder (PTSD), obesity, and diabetes.<sup>14–19</sup>

Given the critical role in regulating stress responses, the eCB system has emerged as a promising therapeutic target for the prevention and treatment of stress-related psychopathology.<sup>16,20</sup> For example, pharmacologic interventions that enhance AEA concentrations through



**Table 1. Included samples on acute exercise (N= 40 samples reported in N= 22 articles)**

Type	First author (year)	Condition	Strain of animal	Sample size (n)	Age (mean ± SD)	Gender (% female)	Race/ ethnicity (%)	Type of exercise	Exercise modality
Human studies									
	Patients, including those with pre-existing conditions								
	Crombie (2020) <sup>88</sup>	Patients with PTSD	N/A	HC: n= 12 TE: n= 14 PTSD: n= 14	HC: 21.4 ± 3.9 TE: 23.0 ± 5.4 PTSD: 27.6 ± 6.6	HC: 100% F TE: 100% F PTSD: 100% F	HC: 92% W, 8% B, 0% A, 0% M, 0% O TE: 86% W, 0% B, 7% A, 0% M, 7% O PTSD: 64% W, 21% B, 7% A, 0% M, 7% O	Endurance	Treadmill running
	Meyer (2019) <sup>58</sup>	Patients with MDD	N/A	n= 17	40.8 ± 14.8	100% F	N/R	Endurance	Electronically braked cycle ergometer
	Crombie (2019) <sup>80</sup>	Patients with PTSD	N/A	HC: n= 10 PTSD: n= 10	HC: 22.0 ± 6.1 PTSD: 25.2 ± 8.1	HC: 70% F PTSD: 80% F	HC: 70% W, 0% B, 20% A, 10% M, 0% O PTSD: 90% W, 0% B, 10% A, 0% M, 0% O	Endurance	Treadmill running or incline walking
	Stensson (2019) <sup>49</sup>	Patients with CNSP	N/A	HC: n= 11 CNSP: n= 21	HC: 37.7 ± 15.9 CNSP: 50.8 ± 12.9	HC: 55% F CNSP: 76% F	N/R	Endurance	Arm cycling
	Brellenthin (2019) <sup>44,b</sup>	Patients with Substance Abuse Disorder	N/A	Treatment as usual with exercise: n= 21	35.1 ± 10.2	45% F	64% W, 2% B, 0% A, 1% M, 1% O	Endurance	Treadmill incline walking
	Crombie (2018) <sup>30</sup>	Patients with PTSD	N/A	HC: n= 12 PTSD: n= 12	HC: 22.0 ± 4.7 PTSD: 26.1 ± 6.7	HC: 75% F PTSD: 75% F	N/R	Endurance	Treadmill running or incline walking
	Healthy volunteers								
	Marin Bosch (2020) <sup>46</sup>	Healthy volunteers	N/A	n= 15	23.2 ± 4.2	0% F	N/R	Endurance	Cycling
	Hughes (2020) <sup>89</sup>	Healthy, recreationally active volunteers	N/A	n= 12	29.0 ± 6.0	17% F	N/R	Strength	Light load RE, BFR-RE, BFR-RE with high pressure, and heavy load RE
	Stone (2018) <sup>90</sup>	Healthy volunteers	N/A	n= 9	61.0	100% F	N/R	Endurance	Cycling and dancing

Exercise duration	Exercise intensity	eCB collection method	eCB collection timepoints	Significant reported change in AEA	Significant reported change in 2-AG	Significant reported change in other eCBs	Additional outcomes <sup>a</sup>
30 min of running on a treadmill at a moderate-intensity exercise with 5 min warm-up and cool-down	70–75% AAMHR	Standard blood draw	Collected immediately before and after exercise	HC: AEA ↑ TE: AEA ↑ PTSD: AEA ↑	HC: 2-AG ↑ TE: 2-AG ↑ PTSD: 2-AG ↑	HC: OEA ↑ PEA ↑ 2-OG ↑ TE: OEA ↑ PEA ↑ 2-OG ↑ PTSD: OEA ↑ PEA ↑ 2-OG ↑	HC: Anxiety ↓ Fear ↓ Improvements in mood TE: Anxiety ↓ Fear ↓ Improvements in mood PTSD: Anxiety ↓ Fear ↓ Improvements in mood
30 min of cycling, either (1) at a moderate intensity or (2) at a preferred intensity, each with 5 min warm-up and cool-down	Ratings of perceived exertion of "13"	Standard blood draw	Collected immediately before and as quickly as possible after the session ended, always within 10 min post-exercise	Prescribed: AEA ↑ Preferred: No AEA changes	Prescribed: No 2-AG changes Preferred: No 2-AG changes	Prescribed: OEA ↑ No PEA, 2-OG changes Preferred: No OEA, PEA, 2-OG changes	Prescribed: Improvements in mood related to eCB changes Preferred: Improvements in mood not related to eCB changes
30 min of running or walking on a treadmill at a moderate-intensity exercise with 5 min warm-up and cool-down	70–75% AAMHR	Standard blood draw	Collected immediately before and after exercise	HC: AEA ↑ PTSD: AEA ↑	HC: 2-AG ↑ PTSD: No 2-AG changes	HC: OEA ↑ No PEA, 2-OG changes PTSD: OEA ↑ No PEA, 2-OG changes	N/A
A 30-min session of arm cycling	N/R	Standard blood draw	Collected immediately before and 60 min after exercise	HC: AEA ↓ CNSP: No AEA changes	HC: No 2-AG changes CNSP: No 2-AG changes	HC: No OEA, PEA, SEA changes CNSP: No OEA, PEA, SEA changes	HC: Glutamate/AEA ratio ↑ CNSP: No glutamate/AEA ratio changes
30 min of moderate-intensity treadmill incline walking	70–75% AAMHR	Standard blood draw	Collected within 5 min before and after exercise	AEA ↑	No 2-AG changes	N/A	Acute improvements in mood and reductions in perceived stress and drug craving
30 min of walking or running on a treadmill at a moderate intensity with 10 min warm-up	70–75% AAMHR	Standard blood draw	Collected immediately before and after exercise	HC: AEA ↑ PTSD: AEA ↑	HC: 2-AG ↑ PTSD: 2-AG ↑	HC: OEA ↑ No PEA, 2-OG changes PTSD: OEA ↑ No PEA, 2-OG changes	HC: Improvements in mood Pain ↓ PTSD: Improvements in mood Pain ↓
A 30-min session of cycling at a moderate intensity and 15 min of cycling at a high intensity the next day, each with a 3 min warm-up and cool-down	Moderate intensity: 70% MHR High intensity: 80% MHR	Standard blood draw	Collected immediately before and after exercise	Moderate intensity: AEA ↑ High intensity: AEA ↑	N/A	N/A	Hippocampus activation ↑ Motor sequence learning ↑
Light load RE, BFR-RE, BFR-RE with high pressure: 4 sets (30, 15, 15, and 15 repetitions, respectively) of unilateral leg press exercise with 30 sec interser rest periods. Heavy load RE: 4 sets of 10 repetitions of unilateral leg press exercise with 53 sec interser rest periods.	Light load RE, BFR-RE, BFR-RE with high pressure: 30% one rep max Heavy load RE: 70% one rep max	Standard blood draw	Collected immediately before, 5 min after, 10 min after, and 24 h after exercise	N/A	Light load RE, BFR-RE, BFR-RE with high pressure, and heavy load RE: No 2-AG changes (decrease for heavy load RE after 24 h)	N/A	Beta-endorphin concentration ↑ Pain ↓
One 30-min session of cycling and one 30 min session of dancing	N/R	Standard blood draw	Collected immediately before and after exercise	Cycling: No AEA changes Dancing: No AEA changes	N/A	Cycling: OEA ↑, no PEA changes Dancing: no OEA changes, no PEA changes	Cycling: ↓ hunger/appetite Dancing: Improved mood

(continued)

**Table 1. (Continued)**

Type	First author (year)	Condition	Strain of animal	Sample size (n)	Age (mean ± SD)	Gender (% female)	Race/ethnicity (%)	Type of exercise	Exercise modality
	Crombie (2018) <sup>91,c</sup>	Healthy volunteers (placebo condition)	N/A	n = 58	21.0 ± 3.0	50% F	57% W, 17% B, 14% A, 12% M, 0% O	Strength	Isometric handgrip
	Brellenthin (2017) <sup>40</sup>	Healthy volunteers	N/A	Low PA exercisers (preferred and prescribed): n = 11 Moderate PA exercisers (preferred and prescribed): n = 12 High PA exercisers (preferred and prescribed): n = 13	Low PA exercisers (preferred and prescribed): 20.6 ± 2.4 Moderate PA exercisers (preferred and prescribed): 19.8 ± 1.1 High PA exercisers (preferred and prescribed): 22.6 ± 5.5	Low PA exercisers (preferred and prescribed): 50% F Moderate PA exercisers (preferred and prescribed): 50% F High PA exercisers (preferred and prescribed): 50% F	N/R	Endurance	Prescribed treadmill exercise and preferred intensity treadmill exercise. Order was randomized and counterbalanced across participants
	Cedernaes (2016) <sup>47</sup>	Healthy volunteers	N/A	n = 16	22.9 ± 0.7	0% F	N/R	Endurance	Ergometer cycling
	Koltyn (2014) <sup>29</sup>	Healthy volunteers (placebo condition only)	N/A	n = 58	21 ± 3.0	50% F	57% W, 17% B, 14% A, 12% M, 0% O	Strength	Isometric handgrip
	Raichlen (2013) <sup>31</sup>	Healthy volunteers	N/A	n = 10	31.9 ± 12.1	40% F	N/R	Endurance	Treadmill running or walking
	Raichlen (2012) <sup>59</sup>	Healthy volunteers	N/A	n = 10	N/R	N/R	N/R	Endurance	Treadmill running or walking
	Feuerecker (2012) <sup>48</sup>	Healthy, trained hikers	N/A	n = 12	27.6	0% F	N/R	Endurance	Hiking
	Heyman (2012) <sup>56</sup>	Healthy, trained cyclists	N/A	n = 11	23.3 ± 5.1	0% F	N/R	Endurance	Cycling
	Sparling (2003) <sup>41</sup>	Healthy, trained volunteers	N/A	Running: n = 8 Cycling: n = 8	23.8 ± 9.4	Running: 0% F Cycling: 0% F	N/R	Endurance	Running or cycling
Animal studies	King-Himmelreich (2017) <sup>64</sup>	Mice treated with CB1R antagonist and AMP-activated protein kinase	C57BL/6 mice	N/R	6–8 weeks	N/R	N/R	Endurance	Treadmill running

Exercise duration	Exercise intensity	eCB collection method	eCB collection timepoints	Significant reported change in AEA	Significant reported change in 2-AG	Significant reported change in other eCBs	Additional outcomes <sup>a</sup>
Isometric handgrip exercise for 3 min	25% MVC	Standard blood draw	Collected immediately before and within 5 min after exercise	AEA ↑	2-AG ↑	OEA ↑ PEA ↑ 2-OG ↑	See Koltny (2014) <sup>29</sup>
Prescribed exercise: 45 min session of treadmill walking or running Preferred exercise: participants' choice of treadmill exercise intensity and duration	Prescribed: 70–75% VO2max Low PA preferred: 74.7 ± 7.8 Moderate PA preferred: 80.4 ± 7.6 High PA preferred: 74.6 ± 15.5	Standard blood draw	Collected immediately before and within 5 min after exercise	Low PA exercisers (preferred and prescribed): AEA ↑ Moderate PA exercisers (preferred and prescribed): AEA ↑ High PA exercisers (preferred and prescribed): AEA ↑	Low PA exercisers (preferred and prescribed): 2-AG ↑ Moderate PA exercisers (preferred and prescribed): 2-AG ↑ High PA exercisers (preferred and prescribed): 2-AG ↑	Low PA exercisers (preferred and prescribed): OEA ↑ PEA ↑ Moderate PA exercisers (preferred and prescribed): OEA ↑ PEA ↑ High PA exercisers (preferred and prescribed): OEA ↑ PEA ↑	Low PA exercisers (preferred and prescribed): Improvements in mood Moderate PA exercisers (preferred and prescribed): Improvements in mood High PA exercisers (preferred and prescribed): Improvements in mood
Ergometer cycling for 35 min	Watts equivalent to 75% of VO2 reserve	Standard blood draw	Collected immediately before, 15 min after, and 4 h after exercise	No AEA changes	2-AG ↑	OEA ↑ PEA ↑ OEA ↑ No PEA changes	Sleep deprivation ↑ 2-AG levels but no modulation in exercise response
Isometric handgrip exercise for 3 min	25% MVC	Standard blood draw	Collected immediately before and within 5 min after exercise	AEA ↑	2-AG ↑	OEA ↑ PEA ↑ 2-OG ↑ DHEA ↑	PPT ↑ PPR ↓
30 min of treadmill walking or running at one of four intensities. Intensities were randomized across four separate laboratory visits.	Intensity 1: <50% AAMHR Intensity 2: 70% AAMHR Intensity 3: 80% AAMHR Intensity 4: 90% AAMHR	Standard blood draw	Collected immediately before and after exercise	Intensity 1: No AEA changes Intensity 2: AEA ↑ Intensity 3: AEA ↑ Intensity 4: No AEA changes	Intensity 1: No 2-AG changes Intensity 2: No 2-AG changes Intensity 3: No 2-AG changes Intensity 4: No 2-AG changes	N/A	Improved positive affect
30 min of treadmill walking on day 1 and 30 min of treadmill running on day 2	Running: 72.5% ± 2.54% MHR (Froude of 0.71 ± 0.03) Walking: 44.6% ± 1.25% MHR (Froude of 0.26 ± 0.01)	Standard blood draw	Collected immediately before and after exercise	Running: AEA ↑ Walking: No AEA changes	Running: No 2-AG changes Walking: No 2-AG changes	N/A	N/A
Protocol A: Hiking at lower altitude for 4–4.5 h Protocol B: Hiking at higher altitude for 3.5–5.5 h	Protocol A: Hiking at lower altitude of ~1650 m Protocol B: Hiking at higher altitude of ~3380 m (1780 m difference compared with lower altitude)	Standard blood draw	Collected before, immediately after, 18 h after, and 24 h after exercise	Protocol A: AEA ↑ Protocol B: AEA ↑	Protocol A: No 2-AG changes Protocol B: No 2-AG changes	N/A	Hypoxia (higher altitudes) ↑ eCB system activation
60 min of pedaling on an ergometric bicycle, followed by predetermined amount of work equal to 30 min at higher intensity. The total exercise period was 90 min	55% of maximal power output for 60 min, followed by 75% of maximal power output for 30 min	Standard blood draw	Collected at rest, after 60 min of exercise at 55% maximal power output, immediately after the 90 min time trial, and 15 min after exercise.	AEA ↑ after a 90-min exercise period	No 2-AG changes	N/A	BDNF levels ↑ significantly during exercise and ↓ during the 15 min of recovery BDNF and AEA concentrations correlated after exercise
45 min of prescribed exercise	70–80% MHR	Standard blood draw	Collected immediately before and after exercise	Running: AEA ↑ Cycling: AEA ↑	Running: No 2-AG changes Cycling: No 2-AG changes	N/A	N/A
60 min of treadmill running	N/R	Standard blood draw	Collected immediately after, 30 min after, 2 h after, 4 h after, and 24 h after exercise	AEA ↑	N/A	N/A	CB1 ↑, FAAH ↓ Found a significant ↓ in the nociceptive response after a single bout of 1 h treadmill running

(continued)

Table 1. (Continued)

Type	First author (year)	Condition	Strain of animal	Sample size (n)	Age (mean ± SD)	Gender (% female)	Race/ethnicity (%)	Type of exercise	Exercise modality
	Fuss (2015) <sup>92</sup>	Mice	C57BL/6J mice	n = 16	10 weeks	N/R	N/R	Endurance	Wheel running
	Galdino (2014) <sup>93</sup>	Rats injected with CB receptor inverse agonists, eCB metabolizing enzyme inhibitors and an AEA reuptake inhibitor	Male Wistar rats	N/R	N/R	0% F	N/R	Strength	RE (i.e., electrical stimulation to the animal's tail causing them to flex their leg muscle)
	Galdino (2014) <sup>94</sup>	Rats injected with CB receptor inverse agonists, eCB metabolizing enzyme inhibitors and an AEA reuptake inhibitor	Male Wistar rats	N/R	N/R	0% F	N/R	Endurance	Treadmill running
	Raichlen (2012) <sup>59,d</sup>	Dogs and ferrets	Mixed-breed dogs and ferrets	Dogs: n = 8 Ferrets: n = 8	N/R	N/R	N/R	Endurance	Treadmill running and walking

Reported sample size is only for the sample that performed the exercise condition.

<sup>a</sup>Outcomes, including mood, anxiety, stress, pain, fear, hunger, cravings, etc. were all self-reported unless otherwise stated.

<sup>b</sup>Also appears in chronic exercise section.

<sup>c</sup>Same sample as in Koltyn (2014).<sup>29</sup>

<sup>d</sup>Same article as human study by Raichlen (2012).<sup>31</sup>

2-AG, 2-arachidonoylglycerol; 2-OG, 2-oleoylglycerol; A, Asian; AA, arachidonic acid; AAMHR, age-adjusted maximum heart rate; AEA, anandamide; AMP, adenosine monophosphate; B, Black; BDNF, brain-derived neurotrophic factor; BFR-RE, blood flow restriction resistance exercise; CB1R, cannabinoid type 1 receptor; CNSP, chronic neck and shoulder pain; DHEA, docosahexaenoyl ethanolamide; eCB, endocannabinoid; F, female; FAAH, fatty acid amide hydrolase; HC, healthy control; M, mixed; MDD, major depressive disorder; MHR, maximum heart rate; MVC, maximum voluntary contraction; N/A, not applicable; N/R, not reported; O, other; OEA, oleylethanolamide; PEA, palmitoylethanolamide; PPR, pressure pain ratings; PPT, Pressure pain thresholds; PTSD, post-traumatic stress disorder; RE, resistance exercise; SD, standard deviation; TE, trauma-exposed individuals without PTSD; W, White.

FAAH inhibition have been shown to attenuate autonomic stress reactivity and improve fear extinction memory recall in healthy adults.<sup>21</sup> Similarly, administration of low doses of exogenous cannabinoids that act on CB1Rs, such as  $\Delta^9$ -tetrahydrocannabinol, reduces fear and anxiety-like behaviors in animal models,<sup>22</sup> potentiates fear extinction memory recall in healthy adults,<sup>23</sup> and reduces corticolimbic responses to threat in adults with PTSD.<sup>24</sup> Several ongoing or recently completed clinical trials have examined drugs that target the eCB system for stress-related psychiatric disorders, including anxiety (NCT02432703), depression (NCT02498392), substance use disorders (SUDs; NCT03787628), and PTSD (NCT04080427).

Growing research suggests that *nonpharmacological* approaches—particularly exercise—can boost eCB signaling. Historically, the euphoric, analgesic, anxiolytic, and mood-elevating effects of exercise were thought to be mediated, at least in part, by the endogenous

opioid system (i.e., exercise-induced increases in beta-endorphins).<sup>25,26</sup> However, recent studies have challenged the role of endorphins in mediating the beneficial effects of exercise. For example, there is evidence that endorphins cannot cross the blood-brain barrier<sup>27</sup> and blockage of endorphin signaling using an opioid receptor antagonist (e.g., naltrexone) does not block the post-exercise euphoric, analgesic, and anxiolytic effects.<sup>28,29</sup>

Rather, emerging data indicate that the eCB system plays a pivotal role in mediating some of the well-documented effects of exercise, including reductions in pain and anxiety, and improvements in cognitive functioning and mood.<sup>30,31</sup> Indeed, studies suggest a role for eCBs in regulating hippocampal neurogenesis<sup>32,33</sup>; therefore, elevations in circulating eCBs may explain some of the reported beneficial effects of exercise on memory and cognitive functioning. There is also evidence that eCBs may contribute to the

Exercise duration	Exercise intensity	eCB collection method	eCB collection timepoints	Significant reported change in AEA	Significant reported change in 2-AG	Significant reported change in other eCBs	Additional outcomes <sup>a</sup>
5 h of wheel running	N/R	Mice tissues (e.g., heart, lung, skeletal muscle, brain), cerebrospinal fluid, and plasma	Collected 5 h after exercise	AEA ↑	2-AG ↑	OEA ↑ PEA ↑ AA ↑	Anxiety-like behavior ↓ Pain (thermal sensitivity) ↓ Absence of CB1R on GABAergic neurons and blockade of central and peripheral CBRs inhibits anxiolytic and analgesic effects, respectively.
15 sets of 15 repetitions, with a 120 sec rest between each set. The total exercise period was 7.5 min	Load was 70% of one rep max	Cardiac puncture	Collected immediately after exercise	AEA ↑	2-AG ↑	OEA ↑ PEA ↑	Injection of AM251 and AM630 prevents the antinociceptive effect induced by acute RE
Animals ran with a progressive speed at 20 m/min (average time of 49.06 min) and 0% inclination until fatigue	N/R	Cardiac puncture	Collected immediately after exercise	AEA ↑	2-AG ↑	OEA ↑ PEA ↑	Injection of AM251 and AM630 prevents the antinociceptive effect induced by acute aerobic exercise
30 min of walking on day 1 and 30 min of running on day 2	Running (Dogs and Ferrets): Froude numbers of ~0.70 Walking (Dogs and Ferrets): Froude numbers of ~0.25	Standard blood draw	Collected immediately before and after exercise	Dogs: AEA ↑ Ferrets: No AEA changes	Dogs: No 2-AG changes Ferrets: No 2-AG changes	N/A	N/A

motivational or rewarding aspects of exercise through modulation of synaptic activity in reward-related brain regions.<sup>34,35</sup> Furthermore, peripheral eCB levels are readily measured in lipid extracts of plasma or serum obtained from venous blood,<sup>36</sup> making circulating eCBs an excellent potential biomarker for tracking the efficacy of exercise interventions.

While the number of studies examining the impact of exercise on eCB signaling has increased by 200% over the past 5 years (Supplementary Fig. S1), no meta-analyses to date have synthesized the current literature on the impact of exercise on eCB signaling. Furthermore, while previous reviews have been published on the eCB system in general,<sup>36</sup> the role of eCBs in exercise focusing on regulation of skeletal muscle response to exercise,<sup>37</sup> implications for the prevention and treatment of neurological disorders,<sup>37</sup> and molecular and cellular pathways related to aerobic exercise,<sup>38</sup> there have been no comprehensive reviews on the effects of exer-

cise on eCB signaling and potential moderators of these effects.

To address this, we performed a systematic review and meta-analysis of all studies on acute (i.e., single bout) and chronic exercise measuring eCBs. Effects of acute and chronic exercise on eCB concentrations were examined separately, given evidence that they may have different effects.<sup>39</sup> Finally, this is the first review to explore various factors that may influence eCB response to exercise, including acute versus chronic exercise, duration, intensity, modality, patient groups (i.e., with and without pre-existing health conditions), and species (i.e., humans, animal models).

## Methodology

### Search strategy

We searched the MEDLINE (PubMed) database for original articles published through December 31, 2020. Articles were included in the systematic review if they



**Table 2. Included studies on chronic exercise (N = 18 samples reported in N = 12 articles)**

Type	First author (year)	Condition	Strain of animal	Sample size (n)	Age (mean ± SD)	Gender (% female)	Race/ethnicity (%)	Type of exercise	Exercise modality
Human studies									
	Stensson (2020) <sup>45</sup>	Patients with pre-existing conditions Patients with FM	N/A	HC: n = 33 FM: n = 37	HC: 50.3 ± 12.8 FM: 50.1 ± 10.5	HC: 100% F FM: 100% F	N/R	Strength	RE
	Belitardo de Oliveira (2019) <sup>95</sup>	Patients with Episodic Migraines	N/A	HC: n = 12 Migraines: n = 13	HC: 34.7 ± 12.0 Migraines: 37.4 ± 13.8	HC: 83% F Migraine: 85% F	HC: 92% W, 0% B, 8% A, 0% M, 0% O Migraines: 92% W, 0% B, 8% A, 0% M, 0% O	Endurance	Treadmill jogging or walking
	Brellenthin (2019) <sup>44</sup>	Patients with Substance Abuse Disorder	N/A	Treatment as usual with exercise: n = 21	35.1 ± 10.2	45% F	64% W, 2% B, 0% A, 1% M, 1% O	Endurance	Treadmill incline walking
	Fernández-Aranda (2014) <sup>96</sup>	Patients who are obese	N/A	HC: n = 16 Obese: n = 30 Morbid obese: n = 43	HC: 27.6 ± 7.9 Obese: 44.9 ± 12.9 Morbid obese: 43.5 ± 10.2	HC: 100% F Obese: 100% F Morbid obese: 100% F	N/R	Endurance	PA
	Koay (2021) <sup>97</sup>	Healthy, newly enlisted soldiers	N/A	n = 52	22.0 ± 4.0	0% F	N/R	Endurance and strength	Combined strength and endurance program and occupational specific activities such as marching.
	Sadhasivam (2020) <sup>98</sup>	Healthy volunteers	N/A	n = 148	≥ 18.0	Blood draws only: N/R Full sample: 49% F	16% W, 2% B, 74% A, 2% M, 6% O	Balance	Yoga (BSP)
	Belitardo de Oliveira (2019) <sup>99</sup>	Healthy volunteers	N/A	n = 17	39.0 ± 13.4	60% F	41% W, 1% B, 1% A, 0% M, 35% O	Endurance	Treadmill running or walking
Animal studies									
	Dos Santos (2019) <sup>100</sup>	Mice that received carrageenan injection	C57BL/6 female mice	Exercise: n = 6 Cg+ exercise: n = 6	8–10 weeks	Exercise: 100% F Cg+ exercise: 100% F	N/R	Endurance	Swimming
	Thompson (2017) <sup>101</sup>	Mice from HR lines	Trained mice from HR lines	HC: n = 50 HR: n = 50	N/R	HC: 50% F HR: 50% F	N/R	Endurance	Wheel running
	Biedermann (2016) <sup>39</sup>	Mice	C57BL/6 mice	Runners: n = 10 Restricted runners: n = 10	10 weeks	Runners: 0% F Restricted runners: 0% F	N/R	Endurance	Wheel running

Exercise duration	Exercise intensity	eCB collection method	eCB collection timepoints	Significant reported change in AEA	Significant reported change in 2-AG	Significant reported change in other eCBs	Additional outcomes <sup>a</sup>
60-min sessions of RE, 2 times/week for 15 weeks	Weeks 1–2: 40% of one rep max, 15–20 reps, 1–2 sets Weeks 3–5: 60% one rep max, 10–12 reps, 1–2 sets Weeks 6–15: 80% one rep max, 5–8 reps, 1–2 sets	Standard blood draw	Collected before (within 1–7 days) the start of the 15-week exercise interventions and after the intervention (within 1–7 days)	HC: No AEA changes FM: AEA ↑	HC: No 2-AG changes FM: No 2-AG changes	HC: No OEA, PEA changes SEA ↑ FM: No OEA, PEA changes SEA ↓	HC: No pain, depression scorings, or muscle strength changes FM: Pain ↓ Depression scorings ↓ Muscle strength ↑
40-min sessions of walking or jogging on a treadmill, 3 times/week for 12 weeks	Heart-rate equivalent to each individual's ventilatory threshold—additional information N/R	Standard blood draw	Collected before exercise and between 2 and 5 days after the last exercise session or 48 h after the last exercise session within the late follicular phase of the menstrual cycle	HC: AEA ↓ Migraines: AEA ↓	N/A	N/A	HC: No migraine attacks or mood changes Migraines: Migraine attacks ↓ Improvements in mood
30 min of moderate-intensity treadmill incline walking, 3 times/week for 6 weeks	70–75% AAMHR	Standard blood draw	N/A	N/R	N/R	N/A	Acute improvements in mood and reductions in perceived stress and drug craving
PA was monitored using accelerometry for 6 days	Time accumulated in MVPA during waking hours	Standard blood draw	Collected between 8 and 9 am after at least 12 h of fasting	AEA ↑ (all groups combined <sup>b</sup> )	No 2-AG changes	OEA ↑ (all groups combined <sup>b</sup> )	High PA associated with low harm avoidance and high novelty seeking (temperament trait)
80-day physical training program with about 1.3 h of PA each day	68% of the PA in the program was of moderate intensity (4.3–6 METs), while 32% was high intensity (METs > 6)	Standard blood draw	Collected after an 80-day program	N/A	2-AG ↓	N/A	Indole-3-propionate ↑ Fatty acids and ketone body substrates ↓ Increases in dimethylguanidino valeric acid associated with increases in several cardiovascular risk factors Shifts in metabolism across many different substrates
4-day, 3-night yoga retreat	N/R	Standard blood draw	Collected before (up to 2 days before program began) and after exercise (within 2 days after program ended)	AEA ↑	2-AG ↑	DEA ↑ 1-AG ↑ OEA ↑	BDNF levels ↑ Depression ↓ Anxiety ↓ Happiness ↑
40 min of treadmill running or walking, 3 times/week for 12 weeks	Heart rate equivalent to each individual's ventilatory threshold—additional information N/R)	Standard blood draw	Collected before program and within 2–5 days after the last exercise session in program	AEA ↓	N/A	N/A	Reduction in AEA associated with weight loss Improvements in mood
5 days/week of swimming for 3 weeks: Week 1: 15 min Week 2: 30 min Week 3: 45 min Wheel running access for exercise group for 6 days	N/R	Mice spinal cord tissue	Collected immediately after exercise program	Exercise: No AEA changes Cg+ exercise: AEA ↑	N/A	N/A	Spinal CB2R participate in exercise-induced antinociception in mice
	N/R	Cardiac puncture	Collected after exercise program	HC: AEA ↑ HR: AEA ↓	HC: 2-AG ↓ HR: 2-AG ↓	N/A	HC: Female mice had ↓2-AG levels and ↑AEA levels compared with male mice HR: Female mice had ↓2-AG levels and ↑AEA levels compared with male mice
Free access wheel running (all day) or restricted access wheel running (6 h/day) for 9 weeks	N/R	Cardiac puncture	Collected after exercise program	Runners: AEA ↓ Restricted runners: AEA ↓	Runners: No 2-AG changes Restricted runners: No 2-AG changes	Runners: No OEA, PEA, 1-AG, and AA changes Restricted Runners: No OEA, PEA, 1-AG, and AA changes	Runners: Hippocampal gray matter volume ↑ Immature hippocampal neurons ↑ Restricted runners: Immature hippocampal neurons ↑

(continued)

Table 2. (Continued)

Type	First author (year)	Condition	Strain of animal	Sample size (n)	Age (mean ± SD)	Gender (%)	Race/ethnicity (%)	Type of exercise	Exercise modality
	Gamelin (2016) <sup>102</sup>	Rats	Male Wistar rats	HC: n = 7 HFD: n = 7	15 weeks	HC: 0% F HFD: 0% F	N/R	Endurance	Treadmill running
	Hill (2010) <sup>32</sup>	Rats (treated with CB1R antagonist in experiment 2)	Sprague/Dawley rats	n = 35	12 weeks	0% F	N/R	Endurance	Wheel running

<sup>a</sup>Outcomes, including mood, anxiety, stress, pain, fear, hunger, cravings, etc., were all self-reported unless otherwise stated.

<sup>b</sup>Did not report separate results for groups, treated as one sample.

1-AG, 1-arachidonoylglycerol; BSP, Bhava Spandana Program; CBR2, cannabinoid type 2 receptor; DEA, docosatetraethanolamide; FM, fibromyalgia; HFD, high-fat diet; HR, high runner; MVPA, moderate-vigorous physical activity; OEA, oleoylethanolamide; PA, physical activity; SEA, stearyl ethanolamide.

met the following inclusion criteria: (1) measured eCB concentrations in circulation or in tissue, (2) examined eCBs before and after exercise (i.e., within-subject design) or compared eCBs in an exercise versus a non-exercise control group (i.e., between-subject design), (3) examined effects of acute (i.e., single bout) or chronic exercise (e.g., 10-week running program). We included studies on aerobic (e.g., running, cycling, dancing) and resistance (e.g., isometric handgrip, resistance training, yoga) exercise. We included studies in humans, including those with and without pre-existing health conditions (e.g., depression, PTSD, SUDs, fibromyalgia), and animal models, of all ages. Although our search focused on AEA and 2-AG as the most well-characterized eCBs, we also examined eCB-like N-acyl ethanolamides (NAEs) and related compounds (e.g., oleoylethanolamide [OEA], palmitoylethanolamide [PEA], and 2-oleoylglycerol [2-OG]). See Supplementary Material for more information on search strategy and article screening, and Figure 1 for a flow-chart of identified articles and exclusions.

A total of 33 articles were included in the systematic review. Of note, 12 articles included results of separate groups (PTSD vs. trauma-exposed controls, dogs vs. ferrets) and 8 included effects of separate exercise conditions (e.g., preferred vs. prescribed exercise),<sup>40</sup> for a total of 57 samples/conditions. The earliest published study was in 2003.<sup>41</sup> First, we summarize results from all articles on acute and chronic exercise. Next, we report results on subgroups, including (1) articles on healthy humans and (2) articles reporting on moderate-intensity aerobic exercise on humans.

#### Meta-analysis

The 33 articles included in the systematic review were subsequently examined for inclusion in the meta-

analysis. Full data were available for 10 articles (reporting on 24 samples) that examined (1) eCB concentrations before and after acute exercise (within-subject design). There were not enough data (<5 articles) to perform meta-analyses on (2) within-subject effects of chronic exercise, (3) between-subject effects of chronic exercise, or (4) between-subject effects of acute exercise. Thus, we performed a meta-analysis on the articles that examine within-subject effects of acute exercise on eCBs. If an article reported effects in different samples separately (e.g., PTSD, healthy control), samples were considered as unique data points. Given the limited number of articles with data from multiple post-exercise time points (four articles), the meta-analysis focused on the first available measurement of eCBs following acute exercise.

First, we extracted data from each of the 10 articles (24 samples) on eCB concentrations before (pre) and after (post) acute exercise. Extracted data included means, standard deviations (SDs), and sample size (N). Change scores were calculated as post-exercise mean minus pre-exercise mean; therefore positive scores represent increases while negative scores represent decreases in eCBs. SDs for the change scores were estimated from pre- and post-exercise SDs (SD<sub>pre</sub> and SD<sub>post</sub>).<sup>42,43</sup> See Supplementary Material for more information. Meta-analyses were conducted for AEA and 2-AG separately, using RevMan software v.5.4 (Cochrane Community, London, United Kingdom) and fixed effect models. Forest plots were generated for sample-specific effect sizes along with 95% confidence intervals (CIs) and pooled effects. Results were considered significant at  $p < 0.05$  and heterogeneity between studies was tested using a chi-square test for heterogeneity and the  $I^2$  statistic. Follow-up analyses were performed in the following subgroups: (1) articles

Exercise duration	Exercise intensity	eCB collection method	eCB collection timepoints	Significant reported change in AEA	Significant reported change in 2-AG	Significant reported change in other eCBs	Additional outcomes <sup>a</sup>
Treadmill running 1 h/day, 5 days/week for 12 weeks	70–80% of the maximal aerobic velocity	Cardiac puncture	Collected after exercise program	HC: No AEA changes HFD: No AEA changes	HC: No 2-AG changes HFD: No 2-AG changes	HC: No OEA and PEA changes HFD: No OEA and PEA changes	HC: No CB1R, CB2R, or FAAH changes HFD: No CB1R, CB2R, or FAAH changes
Access to wheel for 8 days	N/R	Brain tissue in rats	Collected after exercise program	AEA ↑	No 2-AG changes	N/A	Voluntary exercise ↑ proliferation of progenitor cells in the dentate gyrus of the hippocampus Effect of proliferation was prevented following AM251 treatment

on healthy humans (i.e., adults without a clinical diagnosis) and (2) articles reporting on moderate-intensity aerobic exercise on humans.

### Results of Systematic Review

Overview of studies included in systematic review

Thirty-three articles reporting on 57 samples were included in the systematic review ( $n=1021$  participants, see Table 1). Nine of the 33 articles included patients with pre-existing physical or mental health conditions (e.g., PTSD, fibromyalgia), 15 included strictly healthy volunteers (e.g., no current physical or mental health diagnosis), and 10 included animal models (Tables 1 and 2 and Supplementary Material).

The majority of the 33 articles ( $n=22$  articles, 66.7%) focused on the effects of acute exercise on eCB concentrations (Table 1), and 12 articles examined chronic exercise (Table 2). One article examined both acute and chronic exercise.<sup>44</sup> The most common modalities were walking and running, followed by cycling (Supplementary Fig. S2 and Tables 1 and 2). For human studies of acute exercise, the most frequently tested exercise duration (excluding warm-up and cool-down) was 30 min (55.6%).

Of the 33 articles, 93.9% reported on AEA concentrations, 81.8% reported on 2-AG, 51.5% on OEA, 51.5% on PEA, 18.2% on 2-OG, and few (<7%) examined other related molecules (Tables 1 and 2). The majority of articles ( $n=25$ ) measured eCBs in circulation (plasma and/or serum) using a blood draw with standard venipuncture procedures (75.8%). For articles on acute exercise, the majority ( $n=21$ , 63.6%) measured eCBs immediately after or within 5 min following acute exercise. However, eCBs were also measured 15 min–24 h later. For articles on chronic exercise, the time that eCBs were measured varied from within 5 min<sup>44</sup> to

within 1–7 days post-exercise.<sup>45</sup> All studies included adults (i.e., ages 18+) or mature/adult animals. Around 33.3% of studies reported male-only participants and subjects, 39.4% reported both, and 15.2% reported female only (12.1% did not report). For further description of included studies, see the Supplementary Material.

Systematic review results for AEA concentrations

Acute exercise. Twenty-one of the 22 of the articles (39 samples) that examined the effects of acute exercise measured AEA concentrations. Twenty-nine of the 39 (74.4%) samples demonstrated a significant increase in AEA, 1 (2.6%) showed a significant decrease, and 9 (23.1%) revealed no change in AEA.

Acute exercise: healthy individuals only. Sixteen of the 22 articles on acute exercise examined solely healthy humans or included a healthy control group and 15 of these (25 samples) measured AEA concentrations. Eighteen samples (72%) reported an increase in AEA compared with baseline levels, six samples (24.0%) reported no AEA changes, and one sample (4.0%) reported a decrease in AEA concentrations.

Acute exercise: moderate-intensity aerobic exercise: humans only. Twelve of the 22 acute exercise articles (18 samples) measuring AEA concentrations included a moderate-intensity aerobic acute exercise condition (i.e., running or bicycling between 70% and 80% maximum heart rate [MHR]). Seventeen samples (94.4%) reported an increase in AEA, one reported no AEA changes (5.6%), and none reported a decrease in AEA.

Acute exercise: effects of intensity. Seven of the 22 articles (16 samples) on acute exercise examined the impact of various exercise intensities on AEA concentrations. All seven studies (100%) indicated that

moderate-intensity exercise was associated with greater increases in AEA as compared with less-intense exercise (i.e., <50% MHR). Of note, Marin Bosch et al.<sup>46</sup> found that exercise performed at 80% MHR produces greater increases in AEA concentrations as compared with exercise performed at 70% MHR. However, one study by Raichlen et al.<sup>31</sup> also examined vigorous-intensity exercise (i.e., >90% age adjusted MHR). In that study, vigorous-intensity exercise elicited lower AEA as compared with moderate exercise intensities (70–80% MHR). Two studies compared preferred and prescribed moderate exercise conditions (see Supplementary Material for discussion).

**Chronic exercise.** Eleven of 12 articles (17 samples) examined the effects of chronic exercise on AEA concentrations. However, one<sup>44</sup> did not report AEA before and following the intervention (i.e., pre and post-exercise eCB concentrations averaged across acute exercise sessions throughout [baseline and week 6] the intervention were reported). Therefore, only 10 articles (16 samples) were considered in this section. In particular, we report on AEA concentrations before and after chronic exercise. Six samples (37.5%) revealed a significant increase in AEA, six (37.5%) demonstrated a significant decrease, and four (25%) showed no change in AEA.

**Chronic exercise: healthy individuals only.** Five of the 12 articles on chronic exercise solely examined healthy humans or included healthy control groups, and four of these (4 samples) measured AEA concentrations. One sample reported an increase in AEA, two reported a decrease in AEA, and one reported no changes in AEA following the exercise program.

**Chronic exercise: moderate-intensity aerobic exercise.** There were not enough data to evaluate.

#### Systematic review results for 2-AG

**Acute exercise.** Nineteen articles (35 samples) reported 2-AG concentrations following acute exercise. Twenty samples (57.1%) showed no 2-AG changes, 15 samples (42.9%) exhibited a significant increase in 2-AG following acute exercise, and no studies showed a decrease.

**Acute exercise: healthy individuals only.** Sixteen of the 22 articles on acute exercise solely examined healthy humans or included a healthy control group and 14 of these (22 samples) measured 2-AG concentrations. Thirteen samples (59.1%) reported no 2-AG changes compared with baseline levels, nine samples

(40.9%) reported an increase in 2-AG, and no samples reported decreases in 2-AG concentrations.

**Acute exercise: moderate-intensity aerobic exercise: humans only.** Eleven of the 22 acute exercise articles (17 samples) used a moderate-intensity aerobic exercise (e.g., running or bicycling between 70% and 80% MHR) and measured 2-AG concentrations. Nine samples reported no 2-AG changes (59.1%), eight samples reported an increase in 2-AG (40.9%), and no samples reported a decrease in 2-AG.

**Acute exercise: effects of intensity.** Seven of the 22 articles (14 samples) examined the impact of exercise intensity on 2-AG concentrations. None of the 14 samples demonstrated significant effects of exercise intensity on 2-AG concentrations.

**Chronic exercise.** Eight articles (12 samples) reported 2-AG concentrations following chronic exercise. One sample (8.3%) demonstrated a significant increase in 2-AG following chronic exercise, three (25.0%) showed a significant decrease, and eight (66.7%) showed no changes.

**Chronic exercise: healthy individuals only.** Four of the 12 articles on chronic exercise solely examined healthy humans or included a healthy control group and 3 of these (3 samples) measured 2-AG concentrations. One sample reported an increase in 2-AG, one reported a decrease in 2-AG, and one reported no 2-AG changes following an exercise program.

**Chronic exercise: moderate-intensity aerobic exercise.** There were not enough data to evaluate.

#### Systematic review for eCB-like NAEs and related compounds

Seventeen articles measured OEA and PEA (13 articles acute exercise, 4 chronic exercise). Other eCB-like compounds (e.g., 2-OG, SEA, 1-AG) were measured infrequently. Results for these compounds were inconsistent and showed no clear trend for increases, decreases, or no changes in concentrations. However, one study reported elevations in OEA that lasted 4 h after an acute (30 min) cycling session.<sup>47</sup> See Supplementary Material and Table 1 for full summary.

### Results of Meta-Analysis: Within-Subject Effects of Acute Exercise

#### Acute exercise AEA

Eleven articles (24 samples) were included in the meta-analysis ( $n=335$  participants). The meta-analysis

revealed a significant increase (mean difference=0.15 a.u., 95% CIs=0.15 to 0.15) in AEA concentrations following acute exercise ( $z=1227.58$ ,  $p<0.00001$ ; Fig. 2a). Using the studies that reported AEA concentrations in units of pmol/mL (Fig. 2a), this mean difference was 0.03 pmol/mL (95% CIs=0.02 to 0.03). However, there was also substantial heterogeneity in the effect ( $I^2=100\%$ ), suggesting that the magnitude of the increase varied across articles. Inspection of the effect sizes (Fig. 2a) suggests that moderate-intensity exercise is associated with greater increases in AEA as compared with low-intensity exercise, as revealed by the systematic review.<sup>48</sup> Consistent with observations from the systematic review, in general, prescribed moderate-intensity exercise was associated with greater increases in AEA as compared with preferred (Fig. 2a). In addition to comparing preferred versus prescribed, Brellenthin et al.<sup>40</sup> examined the impact of regular physical activity on exercise-related changes in eCBs across three groups: low ( $\leq 60$  min MVPA per week), moderate (150–299 min MVPA per week), and high ( $\geq 300$  MVPA per week) physical activity groups. Although the authors reported no significant main effects or interactions with group<sup>40</sup> inspection of effect sizes (Fig. 2a) for moderate prescribed sessions suggest that the high moderate vigorous physical activity (MVPA) group demonstrated the greatest exercise-related increases in AEA, followed by the moderate, then low MVPA group. Importantly, participants in that study were asked to abstain from exercise within 24 h of testing to minimize potential carryover effects.<sup>40</sup> Therefore, although acute exercise increased AEA among inactive to highly active individuals, prior exercise history may further augment eCB system activation in response to exercise. Post-exercise collection time may also contribute to the observed heterogeneity. While most studies measured post-exercise eCB concentrations immediately after or within 15 min following exercise, Stensson and Grimby-Ekman<sup>49</sup> collected the post-exercise blood sample 60 min after finishing the exercise and demonstrated smaller effect sizes (Fig. 2a). We observed no other patterns related to modality, collection method, subject group, or other factors.

#### Acute exercise: healthy humans only

We repeated the meta-analysis using 15 samples that included healthy humans and found a significant increase (mean difference=0.18 a.u., 95% CIs=0.18 to 0.18) in AEA concentrations following acute exercise ( $z=1245.84$ ,  $p<0.00001$ ). Using the studies that reported AEA concentrations in units of pmol/mL, this

mean difference was 0.2 pmol/mL (95% CIs=0.2 to 0.2). Heterogeneity remained high ( $I^2=100\%$ ).

#### Acute exercise: moderate-intensity aerobic exercise: humans only

We repeated the meta-analysis using 15 samples that reported effects of a moderate-intensity aerobic exercise condition. There was a significant increase (mean difference=0.14 a.u., 95% CIs=0.13 to 0.14) in AEA concentrations following acute moderate exercise ( $z=205.11$ ,  $p<0.00001$ ). Using the studies that reported AEA concentrations in units of pmol/mL, this mean difference was 0.14 pmol/mL (95% CIs=0.14 to 0.14). Heterogeneity remained high ( $I^2=100\%$ ).

#### Acute exercise 2-AG


Twenty-four samples were included in the 2-AG meta-analysis ( $n=335$ ). Similar to results for AEA, the meta-analysis showed a significant increase in 2-AG (mean difference=0.02 a.u., 95% CI=0.02 to 0.02) following acute exercise ( $z=458.18$ ,  $p<0.00001$ ; Fig. 2b). Using the studies that reported 2-AG concentrations in units of pmol/mL (Fig. 2b), this mean difference was 0.9 pmol/mL (95% CIs=0.9 to 0.9). There was also substantial heterogeneity across samples ( $I^2=100\%$ ). Brellenthin et al.<sup>40</sup> examined both preferred and moderate prescribed exercise conditions and reported larger effect sizes for prescribed relative to preferred conditions (Fig. 2b). However, the authors reported no group-by-time interactions in 2-AG concentrations.<sup>40</sup> Breakdown of studies by modality, duration, sample, and timing of sample collection did not reveal any clear patterns in terms of effects on 2-AG (Fig. 2b).

#### Acute exercise: healthy humans only

We repeated the meta-analysis using 15 samples that included healthy humans and found a significant increase (mean difference=0.02 a.u., 95% CIs=0.02 to 0.02) in 2-AG concentrations following acute exercise ( $z=459.95$ ,  $p<0.00001$ ). Using the studies that reported 2-AG concentrations in units of pmol/mL, this mean difference was 0.02 pmol/mL (95% CIs=0.02 to 0.02). Heterogeneity remained high ( $I^2=100\%$ ).

#### Acute exercise: moderate-intensity aerobic exercise: humans only

We repeated the meta-analysis using 15 samples that reported effects of a moderate-intensity aerobic exercise condition. There was a significant increase (mean difference=0.02 a.u., 95% CIs=0.02 to 0.02) in 2-AG



**FIG. 2.** Forest plots for meta-analyses on effects of acute exercise on (a) AEA and (b) 2-AG concentrations (pmol/mL). Note: some articles reported effects in different samples separately (e.g., PTSD and healthy control groups); therefore, these articles are entered more than once in the meta-analysis and treated as separate subgroups. The total effects (bottom) are reported on a different scale than the study effects. Individual studies show mean difference scores and the pooled results show weighted mean differences and 95% confidence intervals. The size of the block indicates the weight assigned to that study in the meta-analysis and the horizontal line depicts the confidence interval. Thus, larger block sizes indicate studies with larger weight (typically with narrower confidence intervals), which contribute more to the calculation of the summary result. The summary result is presented as a diamond at the bottom. The total around that diamond is circled to draw attention to the total effect. 2-AG, 2-arachidonoylglycerol; AEA, anandamide; PTSD, post-traumatic stress disorder.

concentrations following acute moderate exercise ( $z=205.18$ ,  $p<0.00001$ ). Using the studies that reported 2-AG concentrations in units of pmol/mL, this mean difference was  $-0.07$  pmol/mL (95% CIs =  $-0.08$  to  $-0.07$ ). Heterogeneity remained high ( $I^2=97\%$ ).

#### ECB-like NAEs and related compounds

Eight articles (19 samples) reported PEA concentrations, 7 articles (13 samples) reported OEA, and 6 articles (10 samples) reported 2-OG. Acute exercise was associated with a significant increase in both PEA ( $z=681.21$ ,  $p<0.00001$ ) and OEA concentrations ( $z=75.79$ ,  $p<0.00001$ ); but these results showed significant heterogeneity ( $I^2=100\%$ ). In contrast, acute exercise was associated with a significant decrease in 2-OG concentrations ( $z=26.78$ ,  $p<0.00001$ ) with lower heterogeneity ( $I^2=28\%$ ). See Supplementary Figures S1–S3 for full results and forest plots.

#### Discussion

Our systematic review revealed a consistent increase in AEA concentrations following acute exercise, which was confirmed by our meta-analysis. This increase in AEA was observed across modalities (e.g., running, cycling, resistance exercise) as well as, across pre-clinical and clinical studies, including patients with and without pre-existing health conditions (e.g., depression, PTSD). However, there was substantial variation in magnitude of the increase across samples, which may be related to exercise intensity, timing of sample collection, or other factors. These possibilities are discussed below, and we provide some recommendations for future studies.

With regard to 2-AG, effects of acute exercise were less consistent. In the systematic review, half of the samples demonstrated a significant increase in 2-AG concentrations following acute exercise, while half reported no significant changes. However, the meta-analysis supported a small but significant increase in 2-AG concentrations following acute exercise, with substantial heterogeneity across samples. Both the increase in AEA and 2-AG remained significant when considering the subgroup of healthy adults and moderate-intensity aerobic exercise subgroup, only. Overall, the effects of chronic exercise on circulating eCB concentrations were inconsistent, which may be due to the smaller number of studies examining chronic exercise and substantial heterogeneity across studies.

In this study, we provide the first meta-analytic evidence to support the notion that acute exercise mobi-


lizes eCBs.<sup>36</sup> Post-exercise eCB mobilization in the periphery is thought in part to be related to the need to replenish energy stores,<sup>36</sup> given that CB1Rs are widely distributed in adipose tissues, liver, and skeletal muscle. Centrally, eCB mobilization may contribute to the wide range of cognitive, emotional, and physiological processes associated with exercise, through modulation of the HPA axis, neural progenitor cell proliferation, and glutamate and GABA signaling (for a comprehensive review, see Forteza et al.<sup>38</sup>). Indeed, studies included in this review frequently report that elevations in eCBs are associated with, or accompanied by, mood elevations, reductions in stress, anxiety, and pain, and enhanced cognitive functioning (Tables 1 and 2).

Given evidence that skeletal muscle expresses enzymes that synthesize eCBs,<sup>50,51</sup> the observed increase in circulating eCBs following acute exercise may be produced by skeletal muscle. Our meta-analysis revealed that acute exercise increases AEA, PEA, and OEA concentrations (but not 2-OG, which showed a significant decrease). This is consistent with prior studies showing that PEA and OEA are cosynthesized with AEA (NAPE), but not with 2-OG.<sup>52,53</sup> Although PEA and OEA do not bind to CB1Rs, they may be involved in other well-documented effects of exercise, such as appetite suppression, reduced inflammation, and reduced nociception.<sup>54,55</sup> In addition, exercise has been shown to increase circulating glucocorticoids, which may increase AEA concentrations in the brain.<sup>32</sup> Circulating concentrations of other biomarkers (e.g., brain-derived neurotrophic factor [BDNF]) have also been found to be elevated following acute exercise,<sup>56</sup> which may contribute (independently or in conjunction with eCBs) to neuroplastic and antidepressant effects of exercise.

Although the overall effect size was much smaller than for AEA, our meta-analysis revealed an increase in 2-AG concentrations following acute exercise (Fig. 3). The small effect size may explain some of the inconsistencies in reported results in the literature, particularly for studies with smaller sample sizes. 2-AG biosynthesis occurs separately from AEA (e.g., DAGL) and plays a role in reducing HPA axis activation in response to stressors.<sup>57</sup> A few studies reported that elevations in 2-AG (but not AEA) were associated with reductions in tension, mood disturbance, and negative affect following acute exercise (Tables 1 and 2). Therefore, elevations in 2-AG may have additional or complementary benefits from AEA.

Variation in exercise intensity may explain some of the observed heterogeneity in AEA (but not 2-AG).





**FIG. 3.** Proposed increase in AEA and 2-AG concentrations following moderate acute exercise.

Indeed, several studies report that moderate-intensity exercise is associated with greater increases in AEA as compared with other intensities (Fig. 3).<sup>31,40,46,48,56,58,59</sup> There is also initial evidence for an inverted U-shaped effect of exercise intensity on AEA concentrations, such that moderate intensity is associated with the greatest increases; however, this notion is based on results of one study that examined high-intensity exercise (i.e., ~90% age-adjusted MHR).<sup>31</sup> However, the idea that the optimal eCB response may be at moderate-intensity exercise fits with prior data on other outcomes. Indeed, prior studies that compare effects of exercise intensity commonly report greater improvements in mood and cognitive performance, reductions in stress, and enhanced neurobiological reward response following moderate-intensity compared with low- or high-intensity exercise.<sup>60–62</sup> This also fits with the dual-mode model, proposed by Ekkekakis et al., which suggests that moderate-intensity exercise seems to be optimal for improvements in affect.<sup>63</sup>

There is also some evidence that AEA concentrations continue to increase to 15 mins post-exercise.<sup>31</sup> One study in mice suggest that AEA concentrations remain elevated (with respect to a no-exercise control group) for up to 2 h.<sup>64</sup> However, the duration, shape, and recovery of eCB concentrations following exercise remain open questions (Fig. 3). In addition, we did not find consistent effects of *chronic* exercise on eCB concentrations. Thus, the potential for chronic exercise to modulate basal eCB concentrations or eCB responses to acute stress—including exercise stress—is unclear.

In addition to exercise intensity, several other factors may contribute to the observed variation in eCB mobilization following acute exercise. We found initial evidence that the timing of the post-exercise eCB mea-

surement is important, with at least one study measuring eCBs after a 60-min rest period demonstrating smaller effect sizes than studies that measured eCBs immediately after exercise. Exercise history may also modify eCB responses, with initial evidence that more physically active individuals may show a more robust AEA response to exercise as compared with those with low physical activity. eCB tone or response to stress may also be affected by fasted state, last meal timing and content, recent exercise, circadian timing of exercise, BMI, sex, gender, pre-existing health conditions, genetic variance in the eCB system (e.g., *FAAH*, *CNR1*), sleep restriction, psychotropic medications, oral contraceptives, menstrual stage, recent cannabis or alcohol use, injury or inflammation, or racial/ethnic background.<sup>30,65–73</sup>

Future studies should characterize eCB system functioning at baseline and responses to exercise in various patient or risk groups (e.g., trauma-exposed, first-degree relative with depression), which may inform the pathophysiology of these disorders or inform exercise interventions. Future studies should also standardize the duration, timing of measurements and exercise, time-of-day, fed state (e.g., fasted or standard breakfast), and ask participants to refrain from exercising or using substances (e.g., cannabis, alcohol) before the session. Furthermore, future studies are needed to identify the most effective modalities and durations of exercise for enhancing eCB concentrations, as most of the modalities examined in this review were primarily aerobic in nature. We also found no studies that examine the impact of exercise on children, adolescents, or juvenile animals. Thus, the observed effects of acute exercise on eCBs in adults may not generalize to younger populations.

The involvement of stress in the neurobiology of anxiety, depression, PTSD, and SUDs is well described,<sup>74–76</sup> and emerging data implicate eCB system hypoactivity in the pathophysiology and/or maintenance of these disorders.<sup>16,77,78</sup> Indeed, pre-clinical studies suggest that acute, repeated psychological stress exposure is associated with increased 2-AG and *reduced* AEA concentrations in the brain. Clinical studies have reported increases in circulating concentrations of 2-AG in response to acute social stress.<sup>65,79,80</sup> However, lower basal 2-AG concentrations have been reported in individuals with PTSD as compared with trauma-exposed healthy controls, and lower basal AEA and 2-AG concentrations in unmedicated depressed women as compared with controls.<sup>79,81,82</sup> Given the critical role of eCB signaling in regulating anxiety,

stress, and fear-related behavior, the eCB system has garnered attention as a potential therapeutic target for the prevention and treatment of stress-related psychopathology.

Exercise may be a potent nonpharmacological intervention for a variety of stress-related disorders that could benefit from elevations in eCBs and associated effects on mood, stress, anxiety, pain, cognitive functioning, inflammation, sleep, and appetite. Exercise may also be beneficial for conditions associated with eCB system *hyperactivity*, for example, diabetes, obesity, and inflammation. Given that the eCB system responds to stimuli (i.e., stressors), and due to the fact that exercise is a form of physical stress, administering an acute bout of exercise may be useful for probing eCB system stress reactivity in those at risk for psychopathology.<sup>30</sup> Furthermore, eCB signaling is considered to be critical for fear extinction learning and recall, and prior studies indicate that individuals with stress-related disorders (e.g., PTSD) have impaired fear extinction learning and/or recall.<sup>83</sup> Therefore, the ability of exercise to augment eCB signaling may have significant benefits for the management of stress-related disorders, for example, as an adjunct to extinction-based exposure therapy.<sup>84–87</sup>

Limitations should be mentioned. First, there were not enough data to perform meta-analysis on the effects of chronic exercise on eCB concentrations, or to examine studies on acute exercise separately by species, modality, duration, measurement timing, sex, or other factors. We did, however, examine the potential impact of various factors on results of the systematic review and meta-analysis, to identify potential patterns for future study. Furthermore, we focused on the impact of exercise on eCB concentrations; future studies should also examine the role of endorphins, BDNF, or other signaling systems in mediating or moderating acute exercise effects either in isolation from or in conjunction with the eCB system.

## Conclusions

In this study, we provide evidence from a systematic review and meta-analysis that acute exercise activates the eCB system, that is, increases circulating concentrations of eCBs. Given that disruptions in eCB signaling are linked to several stress-related diseases (e.g., anxiety, depression, PTSD, obesity, and diabetes) exercise is a promising nonpharmacological approach for the prevention and treatment of stress-related psychopathology through its potential impacts on eCB signaling. However, the wide heterogeneity observed

across studies to-date suggests that there is a critical need for standardized, well-powered studies to examine (1) the usefulness of exercise as a probe for eCB system functioning in disease or at-risk states, (2) the shape of the eCB response and recovery following acute exercise, (3) factors that modify eCB response to exercise, (4) ability for chronic exercise to modulate basal eCB concentrations and eCB response to stress, and (5) exercise as a preventive or therapeutic intervention.

## Authors' Contributions

S.D., B.B., and H.M. performed the systematic review. C.C. and H.M. performed the analyses. S.D., B.B., C.C., K.C., C.R., M.H., and H.M. contributed to writing and reviewing. All authors approved the article.

## Author Disclosure Statement

No competing financial interests exist.

## Funding Information

Ms. Desai received an Undergraduate Research Creative Project (UROP) award from Wayne State University. Dr. Marusak is supported by the National Institute of Mental Health award K01MH119241 and Children's Foundation award R1-2021-31. Funding sources had no role in this review.

## Supplementary Material

Supplementary Data

Supplementary Figure S1

Supplementary Figure S2

Supplementary Figure S3

## References

- Hillard CJ. Stress regulates endocannabinoid-CB1 receptor signaling. *Semin Immunol.* 2014;26:380–388.
- Kruk-Slomka M, Dzik A, Budzynska B, et al. Endocannabinoid system: the direct and indirect involvement in the memory and learning processes—a short review. *Mol Neurobiol.* 2017;54:8332–8347.
- Kesner AJ, Lovinger DM. Cannabinoids, endocannabinoids and sleep. *Front Mol Neurosci.* 2020;13:125.
- Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. *Int J Mol Sci.* 2018;19:833.
- Castillo PE, Younts TJ, Chávez AE, et al. Endocannabinoid signaling and synaptic function. *Neuron.* 2012;76:70–81.
- Burns HD, Van Laere K, Sanabria-Bohórquez S, et al. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. *Proc Natl Acad Sci U S A.* 2007; 104:9800–9805.
- Cabral GA, Griffin-Thomas L. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. *Expert Rev Mol Med* 2009;11:e3.
- Kendall DA, Yudowski GA. Cannabinoid receptors in the central nervous system: their signaling and roles in disease. *Front Cell Neurosci.* 2016;10: 294.

9. Herkenham M, Lynn AB, Johnson MR, et al. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. *J Neurosci.* 1991;11:563–583.
10. Marsicano G, Kuner R. Anatomical distribution of receptors, ligands and enzymes in the brain and in the spinal cord: circuitries and neurochemistry. In: Köfalvi A (ed.) *Cannabinoids and the Brain.* Boston, MA: Springer, 2008, pp. 161–201.
11. Dean C. Endocannabinoid modulation of sympathetic and cardiovascular responses to acute stress in the periaqueductal gray of the rat. *Am J Physiol Regul Integr Comp Physiol.* 2011;300:R771–R779.
12. Cota D. The role of the endocannabinoid system in the regulation of hypothalamic-pituitary-adrenal axis activity. *J Neuroendocrinol.* 2008;20(Suppl 1):35–38.
13. deRoon-Cassini TA, Stollenwerk TM, Beatka M, et al. Meet your stress management professionals: the endocannabinoids. *Trends Mol Med.* 2020;26:953–968.
14. Engeli S. Dysregulation of the endocannabinoid system in obesity. *J Neuroendocrinol.* 2008;20(Suppl 1):110–115.
15. Pagotto U, Vicennati V, Pasquali R. The endocannabinoid system and the treatment of obesity. *Ann Med.* 2005;37:270–275.
16. Hill MN, Campolongo P, Yehuda R, et al. Integrating endocannabinoid signaling and cannabinoids into the biology and treatment of post-traumatic stress disorder. *Neuropsychopharmacology.* 2018;43:80–102.
17. Charytoniuk T, Zywno H, Konstanynowicz-Nowicka K, et al. Can physical activity support the endocannabinoid system in the preventive and therapeutic approach to neurological disorders? *Int J Mol Sci.* 2020;21:4221.
18. Mechoulam R, Parker LA. The endocannabinoid system and the brain. *Annu Rev Psychol.* 2013;64:21–47.
19. Cheung KAK, Peiris H, Wallace G, et al. The interplay between the endocannabinoid system, epilepsy and cannabinoids. *Int J Mol Sci.* 2019;20:6079.
20. Mayo LM, Rabinak CA, Hill MN, et al. Targeting the endocannabinoid system in the treatment of PTSD: a promising case of preclinical-clinical translation? *Biol Psychiatry.* 2021. [Epub ahead of print]; DOI: 10.1016/j.biopsych.2021.07.019.
21. Mayo LM, Asratian A, Lindé J, et al. Elevated anandamide, enhanced recall of fear extinction, and attenuated stress responses following inhibition of fatty acid amide hydrolase: a randomized, controlled experimental medicine trial. *Biol Psychiatry.* 2020;87:538–547.
22. Patel S, Roelke CT, Rademacher DJ, et al. Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. *Eur J Neurosci.* 2005;21:1057–1069.
23. Rabinak CA, Angstadt M, Sripada CS, et al. Cannabinoid facilitation of fear extinction memory recall in humans. *Neuropharmacology.* 2013;64:396–402.
24. Rabinak CA, Blanchette A, Zabik NL, et al. Cannabinoid modulation of corticolimbic activation to threat in trauma-exposed adults: a preliminary study. *Psychopharmacology (Berl).* 2020;237:1813–1826.
25. Morgan WP. Affective beneficence of vigorous physical activity. *Med Sci Sports Exerc.* 1985;17:94–100.
26. Dishman RK, O'Connor PJ. Lessons in exercise neurobiology: the case of endorphins. *Ment Health Phys Act.* 2009;2:4–9.
27. Pardridge WM, Triguero D, Buciaci JL. Beta-endorphin chimeric peptides: transport through the blood-brain barrier in vivo and cleavage of disulfide linkage by brain. *Endocrinology.* 1990;126:977–984.
28. Siebers M, Biedermann SV, Bindila L, et al. Exercise-induced euphoria and anxiolysis do not depend on endogenous opioids in humans. *Psychoneuroendocrinology.* 2021;126:105173.
29. Koltyn KF, Brellenthin AG, Cook DB, et al. Mechanisms of exercise-induced hypoalgesia. *J Pain.* 2014;15:1294–1304.
30. Crombie KM, Brellenthin AG, Hillard CJ, et al. Psychobiological responses to aerobic exercise in individuals with posttraumatic stress disorder. *J Trauma Stress.* 2018;31:134–145.
31. Raichlen DA, Foster AD, Seillier A, et al. Exercise-induced endocannabinoid signaling is modulated by intensity. *Eur J Appl Physiol.* 2013;113:869–875.
32. Hill MN, Titterness AK, Morrish AC, et al. Endogenous cannabinoid signaling is required for voluntary exercise-induced enhancement of progenitor cell proliferation in the hippocampus. *Hippocampus.* 2010;20:513–523.
33. Wolf SA, Bick-Sander A, Fabel K, et al. Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis. *Cell Commun Signal.* 2010;8:12.
34. Dubreucq S, Koehl M, Abrous DN, et al. CB1 receptor deficiency decreases wheel-running activity: consequences on emotional behaviours and hippocampal neurogenesis. *Exp Neurol.* 2010;224:106–113.
35. Dubreucq S, Durand A, Matias I, et al. Ventral tegmental area cannabinoid type-1 receptors control voluntary exercise performance. *Biol Psychiatry.* 2013;73:895–903.
36. Hillard CJ. Circulating endocannabinoids: from whence do they come and where are they going? *Neuropsychopharmacology.* 2018;43:155–172.
37. Schönke M, Martinez-Tellez B, Rensen PC. Role of the endocannabinoid system in the regulation of the skeletal muscle response to exercise. *Curr Opin Pharmacol.* 2020;52:52–60.
38. Forteza F, Giorgini G, Raymond F. Neurobiological processes induced by aerobic exercise through the endocannabinoidome. *Cells.* 2021;10:938.
39. Biedermann SV, Auer MK, Bindila L, et al. Restricted vs. unrestricted wheel running in mice: effects on brain, behavior and endocannabinoids. *Horm Behav.* 2016;86:45–54.
40. Brellenthin AG, Crombie KM, Hillard CJ, et al. Endocannabinoid and mood responses to exercise in adults with varying activity levels. *Med Sci Sports Exerc.* 2017;49:1688–1696.
41. Sparling PB, Giuffrida A, Piomelli D, et al. Exercise activates the endocannabinoid system. *Neuroreport.* 2003;14:2209–2211.
42. Forbes SC, Candow DG, Krentz JR, et al. Changes in fat mass following creatine supplementation and resistance training in adults  $\geq 50$  years of age: a meta-analysis. *J Funct Morphol Kinesiol.* 2019;4:62.
43. Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. *Cochrane Database Syst Rev.* 2019;10:ED000142.
44. Brellenthin AG, Crombie KM, Hillard CJ, et al. Psychological and endocannabinoid responses to aerobic exercise in substance use disorder patients. *Subst Abus.* 2019;1–12.
45. Stensson N, Gerdle B, Ernberg M, et al. Increased anandamide and decreased pain and depression after exercise in fibromyalgia. *Med Sci Sport Exerc.* 2020;52:1617–1628.
46. Marin Bosch B, Bringard A, Logrieco MG, et al. Effect of acute physical exercise on motor sequence memory. *Sci Rep.* 2020;10:15322.
47. Cedernaes J, Fanelli F, Fazzini A, et al. Sleep restriction alters plasma endocannabinoids concentrations before but not after exercise in humans. *Psychoneuroendocrinology.* 2016;74:258–268.
48. Feuerecker M, Hauer D, Toth R, et al. Effects of exercise stress on the endocannabinoid system in humans under field conditions. *Eur J Appl Physiol.* 2012;112:2777–2781.
49. Stensson N, Grimby-Ekman A. Altered relationship between anandamide and glutamate in circulation after 30 min of arm cycling: a comparison of chronic pain subject with healthy controls. *Mol Pain.* 2019;15:1744806919898360.
50. Hutchins-Wiese HL, Li Y, Hannon K. Hind limb suspension and long-chain omega-3 PUFA increase mRNA endocannabinoid system levels in skeletal muscle. *J Nutr Biochem.* 2012;23:986–993.
51. Crespillo A, Suárez J, Bermúdez-Silva FJ, et al. Expression of the cannabinoid system in muscle: effects of a high-fat diet and CB1 receptor blockade. *Biochem J.* 2011;433:175–185.
52. Sagar DR, Gaw AG, Okine BN, et al. Dynamic regulation of the endocannabinoid system: implications for analgesia. *Mol Pain.* 2009;5:59.
53. Ho W-S V, Barrett DA, Randall MD. “Entourage” effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. *Br J Pharmacol.* 2008;155:837–846.
54. Mattace Raso G, Russo R, Calignano A, et al. Palmitoylethanolamide in CNS health and disease. *Pharmacol Res.* 2014;86:32–41.
55. Hazell TJ, Islam H, Townsend LK, et al. Effects of exercise intensity on plasma concentrations of appetite-regulating hormones: potential mechanisms. *Appetite.* 2016;98:80–88.
56. Heyman E, Gamelin FX, Goekint M, et al. Intense exercise increases circulating endocannabinoid and BDNF levels in humans—possible

- implications for reward and depression. *Psychoneuroendocrinology*. 2012;37:844–851.
57. Hillard CJ, Beatka M, Sarvaideo J. Endocannabinoid signaling and the hypothalamic-pituitary-adrenal axis. *Compr Physiol*. 2017;7:1–15.
  58. Meyer JD, Crombie KM, Cook DB, et al. Serum endocannabinoid and mood changes after exercise in major depressive disorder. *Med Sci Sport Exerc*. 2019;51:1909–1917.
  59. Raichlen DA, Foster AD, Gerdeman GL, et al. Wired to run: exercise-induced endocannabinoid signaling in humans and cursorial mammals with implications for the “runner’s high.” *J Exp Biol*. 2012;215(Pt 8):1331–1336.
  60. Ensari I, Sandroff BM, Motl RW. Intensity of treadmill walking exercise on acute mood symptoms in persons with multiple sclerosis. *Anxiety Stress Coping*. 2017;30:15–25.
  61. Paolucci EM, Loukov D, Bowdish DME, et al. Exercise reduces depression and inflammation but intensity matters. *Biol Psychol*. 2018;133:79–84.
  62. Nakagawa T, Koan I, Chen C, et al. Regular moderate- to vigorous-intensity physical activity rather than walking is associated with enhanced cognitive functions and mental health in young adults. *Int J Environ Res Public Health*. 2020;17:614.
  63. Ekkekakis P, Hall EE, Petruzzello SJ. Variation and homogeneity in affective responses to physical activity of varying intensities: an alternative perspective on dose-response based on evolutionary considerations. *J Sports Sci*. 2005;23:477–500.
  64. King-Himmelreich TS, Möser CV, Wolters MC, et al. AMPK contributes to aerobic exercise-induced antinociception downstream of endocannabinoids. *Neuropharmacology*. 2017;124:134–142.
  65. Dlugos A, Childs E, Stuhr KL, et al. Acute stress increases circulating anandamide and other n-acyl ethanolamines in healthy humans. *Neuropsychopharmacology*. 2012;37:2416–2427.
  66. Hassanzadeh P, Rahimpour S. The cannabinergic system is implicated in the upregulation of central NGF protein by psychotropic drugs. *Psychopharmacology (Berl)*. 2011;215:129–141.
  67. Hanlon EC. Impact of circadian rhythmicity and sleep restriction on circulating endocannabinoid (eCB) N-arachidonylethanolamine (anandamide). *Psychoneuroendocrinology*. 2020;111:104471.
  68. Hanlon EC, Tasali E, Leproult R, et al. Circadian rhythm of circulating levels of the endocannabinoid 2 arachidonoylglycerol. *J Clin Endocrinol Metab*. 2015;100:220–226.
  69. Dincheva I, Drysdale AT, Hartley CA, et al. FAAH genetic variation enhances fronto-amygdala function in mouse and human. *Nat Commun*. 2015;6:6395.
  70. Côté M, Matias I, Lemieux I, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. *Int J Obes*. 2007;31:692–699.
  71. Monteleone P, Piscitelli F, Scognamiglio P, et al. Hedonic eating is associated with increased peripheral levels of ghrelin and the endocannabinoid 2-arachidonoyl-glycerol in healthy humans: a pilot study. *J Clin Endocrinol Metab*. 2012;97:E917–E924.
  72. El-Talati MR, Taylor AH, Konje JC. The relationship between plasma levels of the endocannabinoid, anandamide, sex steroids, and gonadotrophins during the menstrual cycle. *Fertil Steril*. 2010;93:1989–1996.
  73. McPartland JM, Guy GW, Di Marzo V. Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. *PLoS One*. 2014;9:e89566.
  74. Ferrari F, Villa RF. The neurobiology of depression: an integrated overview from biological theories to clinical evidence. *Mol Neurobiol*. 2017;54:4847–4865.
  75. Maeng LY, Milad MR. Post-traumatic stress disorder: the relationship between the fear response and chronic stress. *Chronic Stress (Thousand Oaks)*. 2017;1:2470547017713297.
  76. Patriquin MA, Mathew SJ. The neurobiological mechanisms of generalized anxiety disorder and chronic stress. *Chronic Stress (Thousand Oaks)*. 2017;1:2470547017703993.
  77. Silveira KM, Wegener G, Joca SRL. Targeting 2-arachidonoylglycerol signalling in the neurobiology and treatment of depression. *Basic Clin Pharmacol Toxicol*. 2021;129:3–14.
  78. Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. *Lancet Psychiatry*. 2019;6:995–1010.
  79. Hill MN, Miller GE, Carrier EJ, et al. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. *Psychoneuroendocrinology*. 2009;34:1257–1262.
  80. Crombie KM, Leitzelar BN, Brellenthin AG, et al. Loss of exercise- and stress-induced increases in circulating 2-arachidonoylglycerol concentrations in adults with chronic PTSD. *Biol Psychol*. 2019;145:1–7.
  81. Schaefer C, Enning F, Mueller JK, et al. Fatty acid ethanolamide levels are altered in borderline personality and complex posttraumatic stress disorders. *Eur Arch Psychiatry Clin Neurosci*. 2014;264:459–463.
  82. Hill MN, Bierer LM, Makotkine I, et al. Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks. *Psychoneuroendocrinology*. 2013;38:2952–2961.
  83. Maren S, Holmes A. Stress and fear extinction. *Neuropsychopharmacology* 2015;41:58–79.
  84. Keyan D, Bryant RA. The capacity for acute exercise to modulate emotional memories: a review of findings and mechanisms. *Neurosci Biobehav Rev*. 2019;107:438–449.
  85. Tanner MK, Hake HS, Bouchet CA, et al. Running from fear: exercise modulation of fear extinction. *Neurobiol Learn Mem*. 2018;151:28–34.
  86. Crombie KM, Sartin-Tarm A, Sellnow K, et al. Aerobic exercise and consolidation of fear extinction learning among women with posttraumatic stress disorder. *Behav Res Ther*. 2021;142:103867.
  87. Crombie KM, Sartin-Tarm A, Sellnow K, et al. Exercise-induced increases in Anandamide and BDNF during extinction consolidation contribute to reduced threat following reinstatement: preliminary evidence from a randomized controlled trial. *Psychoneuroendocrinology*. 2021;132:105355.
  88. Crombie KM, Cisler JM, Hillard CJ, et al. Aerobic exercise reduces anxiety and fear ratings to threat and increases circulating endocannabinoids in women with and without PTSD. *Ment Health Phys Act*. 2021;20:100366.
  89. Hughes L, Patterson SD. The effect of blood flow restriction exercise on exercise-induced hypoalgesia and endogenous opioid and endocannabinoid mechanisms of pain modulation. *J Appl Physiol*. 2020;128:914–924.
  90. Stone NL, Millar SA, Herrod PJJ, et al. An analysis of endocannabinoid concentrations and mood following singing and exercise in healthy volunteers. *Front Behav Neurosci*. 2018;12:269.
  91. Crombie KM, Brellenthin AG, Hillard CJ, et al. Endocannabinoid and opioid system interactions in exercise-induced hypoalgesia. *Pain Med*. 2018;19:118–123.
  92. Fuss J, Steinle J, Bindila L, et al. A runner’s high depends on cannabinoid receptors in mice. *Proc Natl Acad Sci U S A*. 2015;112:13105–13108.
  93. Galdino G, Romero T, Silva JF, et al. Acute resistance exercise induces antinociception by activation of the endocannabinoid system in rats. *Anesth Analg*. 2014;119:702–715.
  94. Galdino G, Romero TR, Silva JF, et al. The endocannabinoid system mediates aerobic exercise-induced antinociception in rats. *Neuropharmacology* 2014;77:313–324.
  95. Oliveira AB, Ribeiro RT, Mello MT, et al. Anandamide is related to clinical and cardiorespiratory benefits of aerobic exercise training in migraine patients: a randomized controlled clinical trial. *Cannabis Cannabinoid Res*. 2019;4:275–284.
  96. Fernández-Aranda F, Sauchelli S, Pastor A, et al. Moderate-vigorous physical activity across body mass index in females: moderating effect of endocannabinoids and temperament. *PLoS One*. 2014;9:e104534.
  97. Koay YC, Stanton K, Kienzle V, et al. Effect of chronic exercise in healthy young male adults: a metabolomic analysis. *Cardiovasc Res*. 2021;117:613–622.
  98. Sadhasivam S, Alankar S, Maturi R, et al. Inner engineering practices and advanced 4-day isha yoga retreat are associated with cannabimimetic effects with increased endocannabinoids and short-term and sustained improvement in mental health: a prospective observational study of meditators. *Evid Based Complement Altern Med*. 2020;2020:8438272.
  99. Belitardo de Oliveira A, de Mello MT, Tufik S, et al. Weight loss and improved mood after aerobic exercise training are linked to lower plasma anandamide in healthy people. *Physiol Behav*. 2019;201:191–197.
  100. Dos Santos RS, Sorgi CA, Peti APF, et al. Involvement of spinal cannabinoid CB(2) receptors in exercise-induced antinociception. *Neuroscience*. 2019;418:177–188.

101. Thompson Z, Argueta D, Garland Jr. T, et al. Circulating levels of endocannabinoids respond acutely to voluntary exercise, are altered in mice selectively bred for high voluntary wheel running, and differ between the sexes. *Physiol Behav.* 2017;170:141–150.
102. Gamelin FX, Aucouturier J, Iannotti FA, et al. Exercise training and high-fat diet elicit endocannabinoid system modifications in the rat hypothalamus and hippocampus. *J Physiol Biochem.* 2016;73:335–347.

**Cite this article as:** Desai S, Borg B, Cuttler C, Crombie KM, Rabinak CA, Hill MN, Marusak HA (2022) A systematic review and meta-analysis on the effects of exercise on the endocannabinoid system, *Cannabis and Cannabinoid Research* 7:4, 388–408, DOI: 10.1089/can.2021.0113.

### Abbreviations Used

1-AG = 1-arachidonoylglycerol  
 2-AG = 2-arachidonoylglycerol  
 2-OG = 2-oleoylglycerol  
 A = Asian  
 AA = arachidonic acid  
 AAMHR = age-adjusted maximum heart rate  
 AEA = anandamide  
 AMP = adenosine monophosphate  
 B = Black  
 BDNF = brain-derived neurotrophic factor  
 BFR-RE = blood flow restriction resistance exercise  
 BSP = Bhava Spandana Program  
 CB1R = cannabinoid type 2 receptor  
 CB2R = cannabinoid type 2 receptor  
 CIs = confidence intervals

CNSP = chronic neck and shoulder pain  
 DAGL = diacylglycerol lipase  
 DEA = docosatetraenylethanolamide  
 DHEA = docosahexaenoyl ethanolamide  
 eCB = endocannabinoid  
 F = female  
 FAAH = fatty acid amide hydrolase  
 FM = fibromyalgia  
 HC = healthy control  
 HFD = high-fat diet  
 HR = high runner  
 M = mixed  
 MDD = major depressive disorder  
 MHR = maximum heart rate  
 MVC = maximum voluntary contraction  
 MVPA = moderate-vigorous physical activity  
 N/A = not applicable  
 N/R = not reported  
 NAE = N-acylethanolamide  
 NAPE = N-acylphosphatidylethanolamine phospholipase D  
 O = other  
 OEA = oleylethanolamide  
 PA = physical activity  
 PEA = palmitoylethanolamide  
 PPR = pressure pain ratings  
 PPT = pressure pain thresholds  
 PTSD = post-traumatic stress disorder  
 RE = resistance exercise  
 SD = standard deviation  
 SEA = stearylethanolamide  
 SUDs = substance use disorders  
 TE = trauma-exposed individuals without PTSD  
 W = White